Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, Other, Topics Jan 08 | 2025FDA Draft AOM Guidance; Novo/Valo Expand Partnership; Viking Initiates Oral VK2735 Ph2 Trial; Glooko/Hedia Integration; Sana Islet Cell Therapy T1DM Success; Found Expands to Dissolvable Oral SemaglutidePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jan 07 | 2025Novo/Variant Partnership; Metsera Ph2a GLP-RA Data; Tandem/UVA Partnership; Biomea Icovamenib/Semaglutide Preclinical Data; Diamyd Publication; CeQur Financing RoundPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Jan 06 | 2025OFA Responds to Novo’s Petition on Semaglutide Compounding; PreEvnt Announces New Non-Invasive Glucose Monitor; Novo Holdings and Lilly Invest in Orbis Series A FinancingPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jan 03 | 2025Lilly Requests to Join Compounding Lawsuit; 2026 Medicare/Medicaid Obesity Proposal; Novo Petitions FDA For CompoundingPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, SGLT2i, Topics Jan 03 | 2025Holiday Hangover: FDA Approves Zepbound for OSA; NICE Finalizes Tirzepatide Guidelines; Abbott and Dexcom Reach Agreement; Arrowhead Ph1/2a ARO-INHBE Trial in Obesity; AZ Initiates Ph2 MASH Trial; Zealand Petrelintide Commentary; Generic Liraglutide Approvals; Lexicon Receives CRL for ZynquistaPurchase Blast
$599
Posted in: Other, Topics Dec 20 | 2024Dexcom Participates in Oura Funding; Galectin Misses MASH Endpoint in Ph2b/3 TrialPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 20 | 2024Cagrisema Misses Weight Loss TargetPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Dec 20 | 2024FDA Releases Status on GLP-1RA Supply; AZ Initiates Baxdrostat/Dapa Trial in CKD and CV; TIXiMED Announces $2.65M InvestmentPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 18 | 2024Merck Buys Oral GLP-1RA; MetaVia Topline Ph2a MASH Data; Structure Reveals New DACRA Obesity Asset; Novo/Photys Enter Research Partnership; G&L Initiates H2H Tirzepatide Trial; EMA to Discuss Semaglutide Rare Eye Disease Association; Novo/Catalent Deal CompletePurchase Blast
$599
Posted in: Glucose Monitoring, Other, Topics Dec 17 | 2024Dexcom Integrates AI Into Stelo; Biomea Topline Icovamenib T2DM DataPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, Other, Topics Dec 16 | 2024Novo/Catalent Deal Approval; Novo Invests in New Manufacturing Facility; Afrezza Pediatric Results; New Ph2 Quad-Agonist + Tirzepatide TrialPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other, Topics Dec 13 | 2024CHMP Denies Mounjaro OSA Indication; FLOW Positive CHMP Opinion; New Oramed Oral Insulin Study; Diamyd and FDA Align on Accelerated Approval; Noom to Offer Metformin for Weight LossPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Dec 11 | 2024ADA/EASD 2025 Guidelines; Ro/Lilly Zepbound SDV Partnership; Tirzepatide for Addiction TreatmentPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 10 | 2024GLP1-RAs Reduce Blood Clot Risk in T2DM; Zealand Initiates Ph2b Petrelintide Obesity Trial Enrollment; NewAmsterdam Positive CETPi Ph3 HeFH DataPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Dec 09 | 2024December CHMP Agenda; Senseonics Eversense 365 Launch Updates; BioAge Discontinues Ph2 Obesity TrialPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other, Topics Dec 06 | 2024EC Approves Novo/Catalent Deal; Novo Cuts Insulin Business; Twiist AID Webinar; New Pfizer and Novo Obesity Studies; Lilly CDMO AgreementPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 05 | 2024UK Tirzepatide Rollout Plan; Lilly and Amgen Expand Manufacturing Facilities; New Novo GLP-1/GIP RA CKD and Obesity Trials; Insulet Defends US Patent from EOFlowPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 04 | 2024Zepbound Beats Wegovy in H2H Study; Novavax to Sell Manufacturing Facility to Novo; Antag $84M Series A Financing for Ph1 Obesity TrialPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other, Topics Dec 03 | 2024Metsera Initiates Ph2b MET-097 Obesity Trial; Arrowhead Files for Ph1/2a Obesity Trial Initiation; Sanofi Invests in New Beijing Insulin PlantPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Nov 27 | 2024Arrowhead CY Q3 ’24 (FY Q4 ’24) Earnings; Embecta Discontinues Patch Pump; New Medicare and Medicaid Obesity Proposal; EOFlow Wins Legal Battle in the EUPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
